JP2015515462A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515462A5 JP2015515462A5 JP2015501731A JP2015501731A JP2015515462A5 JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5 JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5
- Authority
- JP
- Japan
- Prior art keywords
- blood
- pegylated
- composition
- subject
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 15
- 102000004506 Blood Proteins Human genes 0.000 claims 12
- 108010017384 Blood Proteins Proteins 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 210000004369 blood Anatomy 0.000 claims 9
- 239000008280 blood Substances 0.000 claims 9
- 102000009027 Albumins Human genes 0.000 claims 8
- 108010088751 Albumins Proteins 0.000 claims 8
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 208000007056 sickle cell anemia Diseases 0.000 claims 3
- 239000012503 blood component Substances 0.000 claims 2
- 239000003914 blood derivative Substances 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 239000002086 nanomaterial Substances 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613105P | 2012-03-20 | 2012-03-20 | |
| US61/613,105 | 2012-03-20 | ||
| PCT/US2013/030355 WO2013142135A1 (en) | 2012-03-20 | 2013-03-12 | Method of enhancing efficacy of blood transfusions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015515462A JP2015515462A (ja) | 2015-05-28 |
| JP2015515462A5 true JP2015515462A5 (enExample) | 2016-04-21 |
Family
ID=49223191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501731A Pending JP2015515462A (ja) | 2012-03-20 | 2013-03-12 | 輸血の有効性を高める方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8859499B2 (enExample) |
| EP (1) | EP2827887A4 (enExample) |
| JP (1) | JP2015515462A (enExample) |
| BR (1) | BR112014023200A2 (enExample) |
| CL (1) | CL2014002464A1 (enExample) |
| HK (1) | HK1204267A1 (enExample) |
| IN (1) | IN2014MN02089A (enExample) |
| MX (1) | MX2014011186A (enExample) |
| WO (1) | WO2013142135A1 (enExample) |
| ZA (1) | ZA201407616B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| WO2017120461A1 (en) | 2016-01-08 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| IN2014MN02089A (enExample) * | 2012-03-20 | 2015-09-11 | Einstein Coll Med | |
| EP3079708A4 (en) * | 2013-12-09 | 2017-08-30 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| US20170333566A1 (en) * | 2014-11-14 | 2017-11-23 | Aima Biotech | Conjugated Proteins |
| PL3229843T3 (pl) | 2014-11-25 | 2020-06-29 | Curadigm Sas | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji |
| EP3096160B1 (en) * | 2015-05-20 | 2020-02-26 | Veoneer Sweden AB | An fmcw vehicle radar system |
| JP2018516256A (ja) | 2015-05-28 | 2018-06-21 | ナノビオティックスＮａｎｏｂｉｏｔｉｘ | 治療用ワクチンとしての使用のためのナノ粒子 |
| PT3307296T (pt) | 2015-06-15 | 2022-01-07 | Univ Leland Stanford Junior | Timp2 para uso no tratamento de condições associadas ao envelhecimento |
| US11065277B2 (en) * | 2015-11-09 | 2021-07-20 | Albert Einstein College Of Medicine | Method of ameliorating side effects of sickle cell disease treatments |
| WO2017103914A1 (en) * | 2015-12-17 | 2017-06-22 | Regentis Biomaterials Ltd. | Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof |
| EP3426265B1 (en) | 2016-04-28 | 2021-09-22 | Alkahest, Inc. | Plasma fractions as therapy for tumor growth and progression |
| IL304946A (en) | 2016-08-18 | 2023-10-01 | Alkahest Inc | Blood plasma fractions as a treatment for cognitive disorders associated with aging |
| EA039316B1 (ru) | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| BR112019022402A2 (pt) | 2017-04-26 | 2020-05-19 | Alkahest Inc | regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo |
| EP3655019A4 (en) | 2017-07-18 | 2021-04-21 | Virtech Bio, Inc. | BLOOD SUBSTITUTES INCLUDING HEMOGLOBIN AND METHODS OF MANUFACTURING |
| MX2021004755A (es) | 2018-10-26 | 2021-06-08 | Alkahest Inc | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. |
| JP7773169B2 (ja) * | 2021-02-24 | 2025-11-19 | 学校法人 中央大学 | ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267269A (en) * | 1980-02-05 | 1981-05-12 | Baxter Travenol Laboratories, Inc. | Red cell storage solution |
| JPS56139419A (en) * | 1980-03-31 | 1981-10-30 | Kuraray Co Ltd | Erythrocytic preservative and erythrocytic pharmaceutical for preservation |
| US6129912A (en) * | 1997-09-26 | 2000-10-10 | Uab Research Foundation | Polyethylene glycol-protein compositions which reduce the antigenic display of red blood cells |
| DE69913716T2 (de) * | 1998-09-25 | 2004-10-07 | Oklahoma Med Res Found | Hemmung der sichelbildung von erythrozyten mittels n-l-alpha-aspartyl-l-phenylalanine 1-methylester |
| US6251927B1 (en) * | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| US6875423B1 (en) * | 1999-09-21 | 2005-04-05 | Marcos Intaglietta | Methods for increasing peripheral blood circulation |
| EP1233986A4 (en) * | 1999-11-12 | 2003-01-02 | Baxter Biotech Tech Sarl | HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS |
| US6811778B2 (en) | 2001-09-10 | 2004-11-02 | Biopure Corporation | Method for improving oxygen transport by stored red blood cells |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US7144989B2 (en) * | 2002-03-25 | 2006-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof |
| US7521174B2 (en) * | 2003-12-05 | 2009-04-21 | Albert Einstein College Of Medicine Of Yeshiva University | Universal red blood cells, methods of preparing same, and uses thereof |
| BRPI0516915A (pt) * | 2004-12-01 | 2008-03-11 | Devgen Nv | derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv |
| WO2007058678A2 (en) * | 2005-06-10 | 2007-05-24 | Albert Einstein College Of Medicine Of Yeshiva University | Uses of pegylated albumin |
| WO2006135740A1 (en) * | 2005-06-10 | 2006-12-21 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated hemoglobin and albumin and uses thereof |
| CA2749698C (en) * | 2009-01-30 | 2017-08-01 | Cuthbert O. Simpkins | Resuscitation fluid |
| WO2010117423A2 (en) * | 2009-03-31 | 2010-10-14 | Duke University | A METHOD FOR TREATING A PATIENT HAVING OR AT RISK FOR DEVELOPING A DISORDER ASSOCIATED WITH DECREASED EXPRESSION OF ß2 ADRENERGIC RECEPTORS OR NEED FOR INCREASED ß2 ADRENERGIC RECEPTOR ACTIVITY |
| DK3266463T3 (da) * | 2009-06-09 | 2024-01-08 | Prolong Pharmaceuticals Llc | Hæmoglobinsammensætninger |
| US20110189166A1 (en) * | 2010-01-29 | 2011-08-04 | John Boucher | Methods of treating hemorheologic abnormalities in mammals |
| WO2011106086A1 (en) * | 2010-02-25 | 2011-09-01 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated albumin polymers and uses thereof |
| IN2014MN02089A (enExample) * | 2012-03-20 | 2015-09-11 | Einstein Coll Med | |
| US20170333566A1 (en) | 2014-11-14 | 2017-11-23 | Aima Biotech | Conjugated Proteins |
-
2013
- 2013-03-12 IN IN2089MUN2014 patent/IN2014MN02089A/en unknown
- 2013-03-12 JP JP2015501731A patent/JP2015515462A/ja active Pending
- 2013-03-12 US US13/794,978 patent/US8859499B2/en active Active
- 2013-03-12 HK HK15104771.0A patent/HK1204267A1/xx unknown
- 2013-03-12 EP EP13764824.2A patent/EP2827887A4/en not_active Withdrawn
- 2013-03-12 MX MX2014011186A patent/MX2014011186A/es unknown
- 2013-03-12 WO PCT/US2013/030355 patent/WO2013142135A1/en not_active Ceased
- 2013-03-12 BR BR112014023200A patent/BR112014023200A2/pt not_active IP Right Cessation
-
2014
- 2014-08-07 US US14/454,059 patent/US9498537B2/en active Active
- 2014-09-17 CL CL2014002464A patent/CL2014002464A1/es unknown
- 2014-10-20 ZA ZA2014/07616A patent/ZA201407616B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Scaffold-facilitated locomotor improvement post complete spinal cord injury: Motor axon regeneration versus endogenous neuronal relay formation | |
| JP2014520142A5 (enExample) | ||
| IL294463A (en) | Methods for treating or preventing eye conditions | |
| JP2011088927A5 (enExample) | ||
| NZ592837A (en) | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents | |
| EA201492021A1 (ru) | Антительный состав | |
| JP2017505761A5 (enExample) | ||
| CN102406205B (zh) | 牡蛎多糖果汁饮料 | |
| WO2008064299A3 (en) | Methods of reducing porcine circovirus-associated disease outbreaks | |
| Lieder et al. | Cardioprotection by post-conditioning with exogenous triiodothyronine in isolated perfused rat hearts and isolated adult rat cardiomyocytes | |
| JP2015515462A (ja) | 輸血の有効性を高める方法 | |
| JP2012528890A5 (enExample) | ||
| MX2018013476A (es) | Composiciones para tratar trastornos acido-base. | |
| RU2018123666A (ru) | Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина | |
| Kelly et al. | TNF receptor 2, not TNF receptor 1 enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia | |
| JP2016513523A5 (enExample) | ||
| JP2017522288A5 (enExample) | ||
| CN105400214A (zh) | 一种使用透明质酸交联明胶制备止血棉的方法 | |
| Feng et al. | Adaptive phenol-based hydrogel embedded with metformin nanoparticles targets oxidative stress and ferroptosis for spinal cord injury repair | |
| Ali et al. | HORMONAL INDUCTION OF OVARIAN CYCLICITY AND CONCEPTION RATE IN POSTPARTUM ANESTRUS BUFFALOES. | |
| JP2017525704A5 (enExample) | ||
| Schmidt et al. | Remote ischemic conditioning: the cardiologist's perspective | |
| HK1200355A1 (en) | Treatment of red blood cells | |
| Kumar et al. | Horn cancer in bovines and its management | |
| WO2012075244A3 (en) | Use of hemoglobin effectors to increase the bioavailability of therapeutic gases |